Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: A report from the children's oncology group

167Citations
Citations of this article
100Readers
Mendeley users who have this article in their library.

Abstract

Radiolabeled metaiodobenzylguanidine (mIBG) is a highly sensitive and specific marker for detecting neuroblastoma. A semiquantitative mIBG score (Curie score [CS]) was assessed for utility as a prognostic indicator for a cohort of patients with highrisk metastatic disease. Methods: mIBG scans from 280 patients with mIBG-avid, stage 4 neuroblastoma enrolled on the Children's Oncology Group (COG) protocol A3973 were evaluated at diagnosis (n = 280), after induction chemotherapy (n = 237), and after an autologous stem cell transplantation (n = 178). Individual mIBG scans were evaluated at 10 different anatomic regions, with the scoring of each site (0-3) based on the extent of disease at that anatomic region. Results: There was no correlation between CS at diagnosis and subsequent treatment outcome. Patients with a CS > 2 after induction therapy had a significantly worse event-free survival (EFS) than those with scores ≤ 2 (3-y EFS: 15.4% ± 5.3% vs. 44.9% ± 3.9%, respectively; P < 0.001). A postinduction CS . 2 identified a cohort of patients at greater risk for an event, independent of other known neuroblastoma factors, including age, MYCN status, ploidy, mitosiskaryorrhexis index, and histologic grade. For MYCN-amplified tumors, the presence (CS > 0) versus absence (CS 5 0) of residual mIBG avidity after induction was associated with a significantly worse outcome (3-y EFS: 11.8% ± 7.8% vs. 49.6% ± 7.7%, respectively; P = 0.003). After transplantation, patients with a CS > 0 had an EFS inferior to that of patients with a CS of 0 (3-y EFS: 28.9% ± 6.8% vs. 49.3% ± 4.9%, respectively [n = 133]; P = 0.009). Conclusion: Curie scoring carries prognostic significance in the management of patients with high-risk neuroblastoma. In particular, patients with CSs . 2 after induction have extremely poor outcomes and should be considered for alternative therapeutic strategies. COPYRIGHT © 2013 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Cite

CITATION STYLE

APA

Yanik, G. A., Parisi, M. T., Shulkin, B. L., Naranjo, A., Kreissman, S. G., London, W. B., … Matthay, K. K. (2013). Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: A report from the children’s oncology group. Journal of Nuclear Medicine, 54(4), 541–548. https://doi.org/10.2967/jnumed.112.112334

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free